title: Significance of IL-2, IL-2R, IL-6, and TNF-alpha as a diagnostic test of acute rejection after renal transplantation.
authors.affiliation: Department of Surgery, Keimyung University School of Medicine, Taegu, Korea.
authors.forename: W H
authors.initials: WH
authors.lastname: Cho
authors.forename: H T
authors.initials: HT
authors.lastname: Kim
authors.forename: C Y
authors.initials: CY
authors.lastname: Sohn
authors.forename: C H
authors.initials: CH
authors.lastname: Park
authors.forename: S B
authors.initials: SB
authors.lastname: Park
authors.forename: H C
authors.initials: HC
authors.lastname: Kim
mesh_terms: D000208:Acute Disease; D000328:Adult; D015415:Biomarkers / Q000097:blood; D003937:Diagnosis, Differential; D006084:Graft Rejection / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007376:Interleukin-2 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D019520:Living Donors; D016853:Muromonab-CD3 / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D015850:Interleukin-6; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha